Clinical reference Biomarker Directory
Back to directory

C6 Complement

Established

C6 is a membrane attack complex component; deficiency causes recurrent Neisseria infections, sometimes atypical serotypes.

Also known as Complement component 6
In plain language

C6 is one of the building blocks of the complement system's final "kill switch" against bacteria. Without it, people are more prone to a specific kind of bacterial infection (Neisseria), sometimes from unusual strains not covered by standard vaccines.

Biomarker & context

C6 is a component of the membrane attack complex (MAC), the terminal complement pathway structure that forms a pore in target cell membranes to cause direct lysis, particularly effective against Neisseria bacteria.

What it indicates

As with other terminal complement components, C6 deficiency causes recurrent, though often survivable, Neisseria meningitidis and Neisseria gonorrhoeae infections, sometimes with atypical serotypes (W-135, X, Y, Z rather than the typical A, B, C).

Diagnosis & clinical testing

Diagnosed via abnormal CH50 and AH50 with normal early-pathway components, followed by specific C6 functional assay to pinpoint the terminal pathway defect.

Guiding treatment

Meningococcal vaccination (including serogroups beyond the standard panel, given the atypical serotype pattern) is a key preventive measure once C6 deficiency is identified.

Clinical significance

Terminal pathway deficiency pattern shared with C5, C7, C8, and C9.

References
  1. ScienceDirect Topics. Complement Deficiency — an overview.